The most common genetic alteration in the ALKBH5 gene were amplifications in the sarcomas (>8%), uterine carcinosarcomas, liver hepatocellular carcinoma and pancreatic adenocarcinomas; mutations (1.3%) in the bladder urothelial carcinomas; and deep deletions (>2%) in the diffuse large B-cell lymphomas (Figure 3A). The gene discussed is ALKBH5; the disease is sarcoma.